MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

ConclusionOur results demonstrate that p53 activation mediated by APG-115 promotes antitumor immunity in the tumor microenvironment (TME) regardless of theTrp53 status of tumors per se. Instead, such an effect depends on p53 activation inTrp53 wild-type immune cells in the TME. Based on the data, a phase 1b clinical trial has been launched for the evaluation of APG-115 in combination with pembrolizumab in solid tumor patients including those withTP53mut tumors.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research